Clinical Trial Update: Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) [Phase 1]

View source ↗

Summary

Phase 1 results indicate safety and tolerability of the ABNCoV2 COVID-19 vaccine, with results posted on 2024-02-12. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• ABNCoV2 (ABNCoV2 vaccine)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Covid19, Severe Acute Respiratory Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2024-02-12